Business
Spero Therapeutics Announces Third Quarter 2020 Operating Results and Provides Business Update
Achieved key clinical milestones with positive ADAPT-PO Phase 3 data and SPR720 IND acceptance Conference call and live webcast at 4:30 p.m. EST today
About this update from Spero Therapeutics, Inc.
[{"type":"text","content":"Achieved key clinical milestones with positive ADAPT-PO Phase 3 data and SPR720 IND acceptance\n Conference call and live webcast at 4:30 p.m. EST today CAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced financial results for the third quarter ended September 30, 2020 and provided a business update. “We made significant clinical progress in the third quarter with the announcement that the ADAPT-PO Phase 3 trial met its primary endpoint,” said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics. “The ADAPT-PO trial was a rigorous test for tebipenem HBr, having been the first trial ever to test an all oral regimen against an all IV regimen for the treatment of complicated urinary tract infection (cUTI) and acute pyelonephritis (AP). We are excited by the positive results seen in the ADAPT-PO trial, which were presented at IDWeek 2020. These results highlight the potential benefit oral tebipenem HBr could offer to patients with cUTI and AP, who are in need of a new treatment option that may allow them to avoid unnecessary hospitalizations.” Clinical Highlights and Upcoming Milestones COVID-19 Update: Spero is committed to advancing its clinical programs while protecting the safety and well-being of patients, physicians and their staff. Spero is monitoring the impact of the COVID-19 pandemic on it business and clinical programs. Spero does not foresee material impacts of the COVID-19 pandemic on its clinical plans at this time and is maintaining its current milestone guidance for its pipeline products. Tebipenem HBr:Spero’s lead product candidate, tebipenem HBr, has the potential to be the first oral carbapenem antibiotic, if approved, to treat cUTI, including AP. In September 2020, Spero announced positive data from the ADAPT-PO Phase 3 trial evaluating an all oral regimen of tebipenem HBr head-to-head versus an all intravenous (IV) regimen of ertapenem for the treatment of adults with cUTI, including AP. The ADAPT-PO trial achieved its primary objective, demonstrating that oral tebipenem HBr was statistically non-inferior to intravenous ertapen...